The invention is directed to glycopeptide antibiotics and their aglycones that are engineered to overcome bacterial resistance by replacement of a single, specific peptide carboxamide group in the core peptide of the glycopeptide antibiotic with an amidine group. The amidine pseudopeptide analog of the glycopeptide is effective in killing vancomycin-resistant bacteria at therapeutically achievable concentrations in a patient. For example, a [ψ[C(=NH)NH]Tpg4]-vancomycin aglycon designed to exhibit the dual binding to D-Ala-D-Ala and D-Ala-D-Lac needed to reinstate activity against vancomycin-resistant bacteria has been shown to overcome a common mode of bacterial resistance to the "last resort" antibiotics of the glycopeptide class. The pseudopeptide amidine analogs can be prepared from corresponding pseudopeptide thioamide analogs, which can be prepared synthetically, semi-synthetically, or biosynthetically.
本发明涉及糖肽抗生素及其无糖基物,通过将糖肽抗生素的核心肽中的单一、特定的肽羧酰胺基团替换为
氨基
亚胺基团,以克服细菌抗药性的工程化。糖肽的
氨基
亚胺伪肽类似物在患者体内的治疗可达浓度下有效地杀灭
万古霉素耐药菌。例如,设计用于表现对D-Ala-D-Ala和D-Ala-D-Lac双重结合所需的[ψ[C(=NH)NH]Tpg4]-
万古霉素无糖基物已被证明能克服糖肽类“最后一道防线”抗生素常见的细菌耐药机制。伪肽
氨基亚
胺类似物可以从相应的伪肽
硫酰胺类似物中制备,这些类似物可以通过合成、半合成或
生物合成制备。